Literature DB >> 15557656

Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.

Xin Li1, Jarrod L Erbe, C Virginia Lockatell, David E Johnson, Michael G Jobling, Randall K Holmes, Harry L T Mobley.   

Abstract

This is a follow-up to our previous study using an intranasal vaccine composed of MrpH, the tip adhesin of the MR/P fimbria, and cholera toxin to prevent urinary tract infection by Proteus mirabilis (X. Li, C. V. Lockatell, D. E. Johnson, M. C. Lane, J. W. Warren, and H. L. Mobley, Infect. Immun. 72:66-75, 2004). Here, we have expressed a cholera toxin-like chimera in which the MrpH adhesin-binding domain (residues 23 to 157) replaces the cholera toxin A1 ADP-ribosyltransferase domain. This chimera, when administered intranasally without additional adjuvant, is sufficient to induce protective immunity in mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557656      PMCID: PMC529142          DOI: 10.1128/IAI.72.12.7306-7310.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 2.  Swarming and pathogenicity of Proteus mirabilis in the urinary tract.

Authors:  H L Mobley; R Belas
Journal:  Trends Microbiol       Date:  1995-07       Impact factor: 17.079

3.  Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits.

Authors:  G Hajishengallis; S K Hollingshead; T Koga; M W Russell
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

4.  Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis.

Authors:  X Li; D E Johnson; H L Mobley
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; C Virginia Lockatell; David E Johnson; M Chelsea Lane; John W Warren; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine.

Authors:  A Lee; M Chen
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic Proteus mirabilis.

Authors:  Xin Li; C Virginia Lockatell; David E Johnson; Harry L T Mobley
Journal:  Mol Microbiol       Date:  2002-08       Impact factor: 3.501

8.  Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras.

Authors:  M G Jobling; R K Holmes
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  Biological and biochemical characterization of variant A subunits of cholera toxin constructed by site-directed mutagenesis.

Authors:  M G Jobling; R K Holmes
Journal:  J Bacteriol       Date:  2001-07       Impact factor: 3.490

Review 10.  Recent advances in mucosal vaccines and adjuvants.

Authors:  Kristina Eriksson; Jan Holmgren
Journal:  Curr Opin Immunol       Date:  2002-10       Impact factor: 7.486

View more
  23 in total

1.  Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.

Authors:  Juliette K Tinker; Chadwick T Davis; Britni M Arlian
Journal:  Protein Expr Purif       Date:  2010-05-11       Impact factor: 1.650

Review 2.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

Review 3.  [Treatment and prophylaxis of recurrent urinary tract infections].

Authors:  B Banas; B K Krämer
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

4.  Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice.

Authors:  Gregory A Price; Heather P Masri; Aimee M Hollander; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Vaccine       Date:  2007-08-06       Impact factor: 3.641

5.  Transcriptional analysis of the MrpJ network: modulation of diverse virulence-associated genes and direct regulation of mrp fimbrial and flhDC flagellar operons in Proteus mirabilis.

Authors:  Nadine J Bode; Irina Debnath; Lisa Kuan; Anjelique Schulfer; Maureen Ty; Melanie M Pearson
Journal:  Infect Immun       Date:  2015-04-06       Impact factor: 3.441

6.  Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.

Authors:  Britni M Arlian; Juliette K Tinker
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

7.  Distinct Residues Contribute to Motility Repression and Autoregulation in the Proteus mirabilis Fimbria-Associated Transcriptional Regulator AtfJ.

Authors:  Nadine J Bode; Kun-Wei Chan; Xiang-Peng Kong; Melanie M Pearson
Journal:  J Bacteriol       Date:  2016-07-13       Impact factor: 3.490

Review 8.  Pathogenesis of Proteus mirabilis Infection.

Authors:  Chelsie E Armbruster; Harry L T Mobley; Melanie M Pearson
Journal:  EcoSal Plus       Date:  2018-02

9.  Zinc uptake contributes to motility and provides a competitive advantage to Proteus mirabilis during experimental urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

Review 10.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.